Adjuvant intravesical therapy in intermediate‐risk non‐muscle‐invasive bladder cancer
BJU International · 2024
DOI: 10.1111/bju.16371 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift BJU International, 2024. Verfasst von Ekaterina Laukhtina und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objective
To evaluate the impact of adjuvant therapy on oncological outcomes in patients with intermediate‐risk non‐muscle‐invasive bladder cancer (NMIBC), as due to the poorly‐defined and overlapping diagnostic criteria optimal decision‐making remains challenging in these patients. Patients and Methods In this multicentre study, patients treated with transurethral resection of bladder tumour for Ta disease were retrospectively analysed. All patients with low‐ or high‐risk NMIBC were excluded from the analysis. Associations between adjuvant therapy administration with recurrence‐free survival (RFS) and progression‐free survival (PFS) rates were assessed in Cox regression models.
Results
A total of 2206 patients with intermediate‐risk NMIBC were included in the analysis. Among them, 1427 patients underwent adjuvant therapy, such as bacille Calmette–Guérin ( n = 168), or chemotherapeutic agents, such as mitomycin C or epirubicin ( n = 1259), in different regimens up to 1 year. The median (interquartile range) follow‐up was 73.3 (38.4–106.9) months. The RFS at 1 and 5 years in patients treated with adjuvant therapy and those without were 72.6% vs 69.5% and 50.8% vs 41.3%, respectively. Adjuvant therapy was associated with better RFS (hazard ratio [HR] 0.79, 95% confidence interval [CI] 0.70–0.89, P < 0.001), but not with PFS ( P = 0.09). In the subgroup of patients aged ≤70 years with primary, single Ta Grade 2 70 years, tumour multiplicity, recurrent tumour and tumour size ≥3 cm ( n = 1878), adjuvant intravesical therapy was associated with improved RFS (HR 0.78, 95% CI 0.68–0.88, P < 0.001).
Conclusion
In our study, patients with intermediate‐risk NMIBC benefit from adjuvant intravesical therapy in terms of RFS. However, in patients without risk factors, adjuvant intravesical therapy did not result in a clear reduction in the recurrence rate.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
- Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy.
- Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic.
- Department of Urology, IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University, Milan, Italy.
- S.H. Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China.
- Sorbonne University, GRC 5 Predictive Onco-Uro, AP-HP, Urology, Pitie-Salpetriere Hospital, Paris, France.
ORCID-Profile: Ekaterina Laukhtina, Marco Moschini, Jeremy Yuen-Chun Teoh, Quoc-Dien Trinh, Mohammad Abufaraj, Francesco Soria, Kensuke Bekku, Akihiro Matsukawa
Zitieren
APA
Laukhtina, E., Gontero, P., Babjuk, M., Moschini, M., Teoh, J. Y., Rouprêt, M., Trinh, Q. D., Chlosta, P., Nyirády, P., Abufaraj, M., Soria, F., Klemm, J., Bekku, K., Matsukawa, A., & Shariat, S. F. (2024). Adjuvant intravesical therapy in intermediate‐risk non‐muscle‐invasive bladder cancer. BJU International. https://doi.org/10.1111/bju.16371
Vancouver
Laukhtina E, Gontero P, Babjuk M, Moschini M, Teoh JY, Rouprêt M, et al. Adjuvant intravesical therapy in intermediate‐risk non‐muscle‐invasive bladder cancer. BJU International. 2024. doi:10.1111/bju.16371
BibTeX
@article{Laukhtina2024,
author = {Laukhtina, Ekaterina and Gontero, Paolo and Babjuk, Marko and Moschini, Marco and Teoh, Jeremy Yuen-Chun and Rouprêt, Morgan and Trinh, Quoc-Dien and Chlosta, Piotr and Nyirády, Péter and Abufaraj, Mohammad and Soria, Francesco and Klemm, Jakob and Bekku, Kensuke and Matsukawa, Akihiro and Shariat, Shahrokh F},
title = {Adjuvant intravesical therapy in intermediate‐risk non‐muscle‐invasive bladder cancer},
journal = {BJU International},
year = {2024},
doi = {10.1111/bju.16371}
}
EUVIMED